A Phase II Trial of PSMA ADC in Taxane-Treated mCRPC
Daniel P. Petrylak, MD, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC).
Clinical Pearls
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) presented at the 2014 AUA Annual Meeting.
- Patients with progressive mCRPC progressing after taxane treatment and ECOG PS 0 or 1 were treated with PSMA ADC every 3 weeks.
- Early on, researchers learned that 2.5 mg/kg was too high of a dose and reduced it to 2.3 mg/kg for remaining patients.
- Patients who expressed PSMA on circulating tumor cells and had lack of neuroendocrine markers tended to respond to the antibody complex.
- PSMA ADC was fairly well tolerated. The most common significant adverse events observed were neutropenia and peripheral neuropathy.
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
